Skip to main content
Neal Shore, MD, Urology, Myrtle Beach, SC

NealShoreMDCPI,FACS

Urology Myrtle Beach, SC

Managing Partner,Atlantic Urology Clinics Medical Director, Carolina Urologic Research Center

Dr. Shore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Shore's full profile

Already have an account?

  • Office

    823 82nd Pkwy
    Myrtle Beach, SC 29572
    Phone+1 843-449-1010
    Fax+1 843-497-6171

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1986 - 1990
  • Other
    OtherClass of 1984
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1983

Certifications & Licensure

  • SC State Medical License
    SC State Medical License 1994 - 2025
  • NY State Medical License
    NY State Medical License 1985 - 2008
  • NJ State Medical License
    NJ State Medical License 1990 - 1995
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Real-World Clinical Outcomes with Radium-223 in Metastatic Castration-Resistant Prostate Cancer - Neal Shore 
    Large Urology Group Practice Association, Chicago, Illinois - 11/1/2012
  • Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

  • The EMBARK Trial: An Interview with Neal D. Shore, MD
    The EMBARK Trial: An Interview with Neal D. Shore, MDMay 19th, 2023
  • Pfizer, Astellas Pharma' Xtandi Combo Therapy Cuts Risk of Metastasis, Death by 58 Percent in Prostate Cancer
    Pfizer, Astellas Pharma' Xtandi Combo Therapy Cuts Risk of Metastasis, Death by 58 Percent in Prostate CancerMay 1st, 2023
  • Stockwatch
    StockwatchMay 1st, 2023
  • Join now to see all

Professional Memberships